Changling Li1, Yanbo Li1, Mengmeng Ma1, Yang Zhang1, Jiajia Bao1, Wenjing Ge1, Yanqin Liu1, Cheng Peng1, Li He2. 1. Department of Neurology, West China Hospital of Sichuan University, No. 37 Wainan Guoxue Xiang, Chengdu, 610041, China. 2. Department of Neurology, West China Hospital of Sichuan University, No. 37 Wainan Guoxue Xiang, Chengdu, 610041, China. heli2003new@126.com.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) bring about a range of psychological distress and symptom deterioration to headache patients especially to some migraineurs. Compared to migraineurs or normal control, medication overuse headache (MOH) patients are more likely to experience a worse psychological distress and poorer outcome in non-COVID-19 time. However, in COVID-19 pandemic, whether MOH patients would have greater physical and mental symptom deterioration or worse relief of headache symptoms and medications overuse remained unclear. We aim to investigate the impact of COVID-19 on MOH patients to guide for a better management in this study. METHODS: We enrolled MOH patients who were diagnosed and treated at headache clinic of West China Hospital. Information of the pre-pandemic 3 months period and COVID-19 pandemic period was collected. Univariate and multivariate logistic regression were performed to identify independent factors associated with changes in headache symptoms and drug withdrawal. RESULTS: Seventy-eight MOH patients were enrolled into the study ultimately. In comparison to pre-pandemic period, fewer MOH patients reported decreased headache days, intensity and days with acute medications per month during the pandemic. Available access to regular prophylactic medications was significantly associated with a reduction of at least 50% in headache days and decrease in headache intensity per month with respective odds ratios of 39.19 (95% CI 3.75-409.15, P = 0.002) and 10.13 (95% CI 2.33-44.12, P = 0.002). Following abrupt withdrawal and high educational level were both significant factors in decreasing headache intensity. Male sex was significantly associated with decrease in days with acute medication per month during the pandemic (odds ratios 4.78, 95%CI 1.44-15.87, P = 0.011). CONCLUSIONS: Our findings reflect that MOH patients experienced a worse relief of headache symptoms and drug withdrawal during the pandemic. Available access to regular prophylactic medications was the significant independent factor for improvement of headache symptoms. Male sex was significantly associated with decreased days with acute medications per month.
BACKGROUND:Coronavirus disease 2019 (COVID-19) bring about a range of psychological distress and symptom deterioration to headachepatients especially to some migraineurs. Compared to migraineurs or normal control, medication overuse headache (MOH) patients are more likely to experience a worse psychological distress and poorer outcome in non-COVID-19 time. However, in COVID-19 pandemic, whether MOH patients would have greater physical and mental symptom deterioration or worse relief of headache symptoms and medications overuse remained unclear. We aim to investigate the impact of COVID-19 on MOH patients to guide for a better management in this study. METHODS: We enrolled MOH patients who were diagnosed and treated at headache clinic of West China Hospital. Information of the pre-pandemic 3 months period and COVID-19 pandemic period was collected. Univariate and multivariate logistic regression were performed to identify independent factors associated with changes in headache symptoms and drug withdrawal. RESULTS: Seventy-eight MOH patients were enrolled into the study ultimately. In comparison to pre-pandemic period, fewer MOH patients reported decreased headache days, intensity and days with acute medications per month during the pandemic. Available access to regular prophylactic medications was significantly associated with a reduction of at least 50% in headache days and decrease in headache intensity per month with respective odds ratios of 39.19 (95% CI 3.75-409.15, P = 0.002) and 10.13 (95% CI 2.33-44.12, P = 0.002). Following abrupt withdrawal and high educational level were both significant factors in decreasing headache intensity. Male sex was significantly associated with decrease in days with acute medication per month during the pandemic (odds ratios 4.78, 95%CI 1.44-15.87, P = 0.011). CONCLUSIONS: Our findings reflect that MOH patients experienced a worse relief of headache symptoms and drug withdrawal during the pandemic. Available access to regular prophylactic medications was the significant independent factor for improvement of headache symptoms. Male sex was significantly associated with decreased days with acute medications per month.
Authors: Hans-Christoph Diener; David Dodick; Stefan Evers; Dagny Holle; Rigmor Hoejland Jensen; Richard B Lipton; Frank Porreca; Stephen Silberstein; Todd Schwedt Journal: Lancet Neurol Date: 2019-06-04 Impact factor: 44.182
Authors: M Linde; A Gustavsson; L J Stovner; T J Steiner; J Barré; Z Katsarava; J M Lainez; C Lampl; M Lantéri-Minet; D Rastenyte; E Ruiz de la Torre; C Tassorelli; C Andrée Journal: Eur J Neurol Date: 2011-12-05 Impact factor: 6.089
Authors: H C Diener; F Antonaci; M Braschinsky; S Evers; R Jensen; M Lainez; E S Kristoffersen; C Tassorelli; K Ryliskiene; J A Petersen Journal: Eur J Neurol Date: 2020-05-19 Impact factor: 6.089
Authors: L Bendtsen; Sb Munksgaard; C Tassorelli; G Nappi; Z Katsarava; M Lainez; Ja Leston; R Fadic; S Spadafora; A Stoppini; R Jensen Journal: Cephalalgia Date: 2013-12-09 Impact factor: 6.292
Authors: Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai Journal: N Engl J Med Date: 2020-01-31 Impact factor: 91.245